{
    "nctId": "NCT04411966",
    "briefTitle": "Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer",
    "officialTitle": "Integrating 18F-FDG PET/CT With 18F-FLT PET/CT in Predicting Treatment Response and Prognosis of Metastatic/Recurrent Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "N/A",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 32,
    "primaryOutcomeMeasure": "Change in 18F-fluorothymidine (18F-FLT) and 18F-fluorodeoxyglucose (18F-FDG) maximal standardized uptake value (SUV) as response to therapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants must have histological evidence of breast cancer of any stage\n* Participants must be diagnosed with metastatic breast cancer\n* Participants should be willing and able to have both PET-CT scans\n* Participants should be eligible for and plan to undergo systemic chemotherapy and should be seen by a oncologist prior to beginning the study\n* Participants should have the ability to understand and the willingness to sign a written informed consent document\n* Participants must sign a study specific consent form prior to registration\n\nExclusion Criteria:\n\n* Patients have been diagnosed with other malignancy\n* Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or significant inflammation at treatment site or psychiatric illness/social situations that would limit compliance with study requirements or whose lab values do not meet the criteria above are excluded\n* Pregnant women are excluded from this study\n* Breast feeding women are excluded from this study",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}